Diagnostic and Prognostic Potential of Serum Cell-Free microRNA-214 in Glioma

Che, Fengyuan; Zhang, Jinling; Zhang, Ming; Xiao, Shuai; Liu, Yan; Zhou, Liangjian; Su, Qiang; You, Cuiping; Lu, Yucheng; Heng, Xueyuan

doi:10.1016/j.wneu.2019.02.009

Cited by 19 publications

(17 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a previous study, Wang et al (54) revealed that serum miR-214 gradually escalated with an increase in glioma grade, and had excellent diagnostic efficacy for gliomas (AUC: 0.885, 95%CI: 0.833-0.926). Additionally, Lai et al (49) showed the outstanding diagnostic value of miR-210 in gliomas with a sensitivity of 0.9127, specificity of 0.725, and AUC of 0.927 (95%CI: 0.889-0.964).…”

Section: Discussionmentioning

confidence: 98%

Circulating MicroRNAs as Promising Diagnostic Biomarkers for Patients With Glioma: A Meta-Analysis

He¹,

Jiang²,

Liu³

et al. 2021

Front. Neurol.

View full text Add to dashboard Cite

Backgrounds and Purpose: Currently, circulating microRNAs (miRNAs) are considered to be non-invasive diagnostic biomarkers in a broad range of tumors. Nevertheless, so far, miRNAs have not been fully applied to the clinic for routine screening in glioma patients. Thus, our goal is to evaluate the diagnostic performance of circulating miRNAs for gliomas via a meta-analysis. The present study is registered on the PROSPERO website, with the number CRD42020195883.Methods: Literature retrieval was implemented in the PubMed, Embase, and Web of Science databases using the established search strategy. We pooled the sensitivity, specificity, and its 95% confidence intervals (CIs) for the included studies using the Stata 14.0 software. In addition, the heterogeneity between studies was assessed via the Q statistics and I2 values calculated by a Chi-square test. A bivariate random effects model was selected due to significant heterogeneity. Specifically, for exploring the factors influencing the heterogeneity, we implemented subgroup and meta-regression analyses. Ultimately, a Deek's funnel plot asymmetry test was used to estimate the potential publication bias.Results: A total of 18 articles covering 24 studies were included, containing 2,170 glioma patients and 1,456 healthy participants. The overall pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC) were 0.84 (95%CI: 0.79–0.87), 0.84 (95%CI: 0.80–0.88), 5.3 (95%CI: 4.1–6.8), 0.19 (95%CI: 0.15–0.25), 27 (95%CI: 18–41), and 0.91 (95%CI: 0.88–0.93), respectively. Additionally, the findings revealed that serum miRNAs and miRNA panels presented superior diagnostic performance.Conclusion: Thus, circulating miRNAs have the potential to serve as diagnostic biomarkers for gliomas, but need to be verified via a large pool of prospective studies. Additionally, specific miRNAs still need to be elucidated in the diagnosis of a glioma, especially in the early screening stage. The findings may provide diagnostic and therapeutic strategies for the glioma population.

show abstract

Section: Discussionmentioning

confidence: 98%

Circulating MicroRNAs as Promising Diagnostic Biomarkers for Patients With Glioma: A Meta-Analysis

He¹,

Jiang²,

Liu³

et al. 2021

Front. Neurol.

View full text Add to dashboard Cite

show abstract

“…MicroRNAs may be ideal blood-based biomarkers as they are easily accessible in body fluids (127), are stable under harsh extrinsic conditions such as significant changes in temperature (128), and are protected from intrinsic conditions such as degradation by RNAses (129). Indeed, microRNAs can be found in biofluids such as serum, plasma, urine and cerebrospinal fluid and have shown to be deregulated in various cancer types such as renal cell carcinoma (130) and melanoma (131).…”

Section: Nucleic Acidsmentioning

confidence: 99%

Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review

et al. 2021

View full text Add to dashboard Cite

BackgroundGliomas are the most common and aggressive tumors of the central nervous system. A robust and widely used blood-based biomarker for glioma has not yet been identified. In recent years, a plethora of new research on blood-based biomarkers for glial tumors has been published. In this review, we question which molecules, including proteins, nucleic acids, circulating cells, and metabolomics, are most promising blood-based biomarkers for glioma diagnosis, prognosis, monitoring and other purposes, and align them to the seminal processes of cancer.MethodsThe Pubmed and Embase databases were systematically searched. Biomarkers were categorized in the identified biomolecules and biosources. Biomarker characteristics were assessed using the area under the curve (AUC), accuracy, sensitivity and/or specificity values and the degree of statistical significance among the assessed clinical groups was reported.Results7,919 references were identified: 3,596 in PubMed and 4,323 in Embase. Following screening of titles, abstracts and availability of full-text, 262 articles were included in the final systematic review. Panels of multiple biomarkers together consistently reached AUCs >0.8 and accuracies >80% for various purposes but especially for diagnostics. The accuracy of single biomarkers, consisting of only one measurement, was far more variable, but single microRNAs and proteins are generally more promising as compared to other biomarker types.ConclusionPanels of microRNAs and proteins are most promising biomarkers, while single biomarkers such as GFAP, IL-10 and individual miRNAs also hold promise. It is possible that panels are more accurate once these are involved in different, complementary cancer-related molecular pathways, because not all pathways may be dysregulated in cancer patients. As biomarkers seem to be increasingly dysregulated in patients with short survival, higher tumor grades and more pathological tumor types, it can be hypothesized that more pathways are dysregulated as the degree of malignancy of the glial tumor increases. Despite, none of the biomarkers found in the literature search seem to be currently ready for clinical implementation, and most of the studies report only preliminary application of the identified biomarkers. Hence, large-scale validation of currently identified and potential novel biomarkers to show clinical utility is warranted.

show abstract

“…Several studies explored the correlation of circulating miRNAs with the histopathological grade of glioma [22,23,28,30,32,33,35,39,41,42,44,45,47,49,52,56,63,64,66,69]. However, this approach is fraught with inaccuracies, as it is increasingly recognized that the histological grade may not always accurately reflect the biological behaviour [6].…”

Section: Cell-free Rnas In Bloodmentioning

confidence: 99%

“…Some miRNAs correlate with patient outcome and can serve as prognostic/predictive biomarkers,[21-23, 25, 26, 32, 33, 35, 37, 39, 40, 42, 45, 46, 49-53, 56-64, 66-68, 70] with the most relevant ones belonging to the miR-221/222 family, which is involved in glioma cell invasion, proliferation and apoptosis, regulating multiple target genes[26]. However, the value of circulating miRNAs as prognostic marker or tool for monitoring tumour growth has been less explored, and in many studies miRNA levels were evaluated just before and after surgery[20,22,23,28,30,39,42,45,48,61,63,68,70] and not in relation to chemotherapy[22,37,59]. Despite the large number of cfRNA molecules examined, only few of them have yielded consistent results across different studies.…”

mentioning

confidence: 99%

Time to focus on circulating nucleic acids for diagnosis and monitoring of gliomas: A systematic review of their role as biomarkers

Méndez¹,

Tremante²,

Regazzo³

et al. 2021

Neuropathology Appl Neurobio

View full text Add to dashboard Cite

Gliomas are diffusely growing tumours arising from progenitors within the central nervous system. They encompass a range of different molecular types and subtypes, many of which have a well-defined profile of driver mutations, copy number changes and DNA methylation patterns. A majority of gliomas will require surgical intervention to relieve raised intracranial pressure and reduce tumour burden. A proportion of tumours, however, are located in neurologically sensitive areas and a biopsy poses a significant risk of a deficit. A majority of gliomas recur after surgery, and monitoring tumour burden of the recurrence is currently achieved by imaging. However, most imaging modalities have limitations in assessing tumour burden and infiltration into adjacent brain, and sometimes imaging is unable to discriminate between tumour recurrence and pseudo-progression.Liquid biopsies, obtained from body fluids such as cerebrospinal fluid or blood, contain circulating nucleic acids or extracellular vesicles containing tumour-derived components.The studies for this systematic review were selected according to PRISMA criteria, and suggest that the detection of circulating tumour-derived nucleic acids holds great promises as biomarker to aid diagnosis and prognostication by monitoring tumour progression, and thus can be considered a pathway towards personalized medicine.

show abstract

Diagnostic and Prognostic Potential of Serum Cell-Free microRNA-214 in Glioma

Cited by 19 publications

References 28 publications

Circulating MicroRNAs as Promising Diagnostic Biomarkers for Patients With Glioma: A Meta-Analysis

Circulating MicroRNAs as Promising Diagnostic Biomarkers for Patients With Glioma: A Meta-Analysis

Blood-Based Biomarkers for Glioma in the Context of Gliomagenesis: A Systematic Review

Time to focus on circulating nucleic acids for diagnosis and monitoring of gliomas: A systematic review of their role as biomarkers

Contact Info

Product

Resources

About